Obesity: A Disease

Obesity Medicine

Obesity: A Disease is the official Obesity Medicine Association (OMA) FREE podcast exploring the many facets of the disease of obesity. Episodes provide valuable insights into this growing problem and better equip clinicians to understand and engage in treating this disease.

  1. 1D AGO

    Episode 126: Industry Insights: Metabolic Resting Rate

    In this Industry Insights episode of Obesity: A Disease, host Dr. Christopher Weber welcomes Dr. Cameron Garber and Dr. Marc Humbert, metabolic testing specialists with Korr Medical Technologies and hosts of the Metabolic Mastery podcast. Dr. Garber and Dr. Humbert join Dr. Christopher Weber for a focused discussion on resting metabolic rate, exploring its role as a vital sign, its application in nutritional planning, and what the future holds for metabolic testing. This episode is sponsored by Korr Medical Technologies. To learn more about Korr’s metabolic test equipment, visit //KORR.com/OMA or visit them at booth #113 at the 2026 Obesity Medicine Conference in San Diego, CA. Episode Guests: Cameron Garber, DPT Marc Humbert, DPT Episode Host: Christopher Weber, MD, FAAP, FACP, CSCS, DABOM, FOMA The opinions expressed in this podcast are those of the individual speakers and do not represent the views or positions of the Obesity Medicine Association (OMA). This content is intended for informational purposes only. Chapters (00:00:01) - Obesity a Disease(00:01:25) - Resting metabolic rate (RMR)(00:06:53) - MRK: Metabolism, Science(00:13:12) - Exercise and Weight Loss(00:20:49) - Resting metabolic rate(00:24:21) - Metabolic rate monitoring(00:29:57) - Cost of care, Medicare, private insurance(00:31:51) - Heart disease and weight loss(00:41:06) - Weight Loss on GLP1s(00:49:43) - The Future of Weight Loss and Management(00:53:59) - Weight Management: Obesity, a Disease

    55 min
  2. 5D AGO

    Episode 125: Industry Insights: Surmount OSA Trial

    In this Industry Insights episode of Obesity: A Disease, host Dr. Christopher Weber welcomes Dr. Kevin Trice, Executive Director in the Global Medical Affairs Division of Cardiometabolic Health at Eli Lilly. Dr. Trice will be speaking today on behalf of Lilly. This material is developed under the direction and sponsorship of Lilly Medical Affairs and is intended for US healthcare professional only. Dr. Trice is an employee of Eli Lilly.  Dr. Kevin Trice joins Dr. Christopher Weber for a focused discussion on the key findings from the SURMOUNT-OSA trial and their implications for clinical practice. Together, they explore how this landmark study informs the evolving management of obesity and obstructive sleep apnea.  This episode is sponsored by Lilly. Episode Guest: Kevin Trice, MD, MBA Episode Host: Christopher Weber, MD, FAAP, FACP, CSCS, DABOM, FOMA Note From the Sponsor *When discussing tirzepatide for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, it’s important to emphasize that its safety profile mirrors what we’ve seen in obesity and diabetes indications. The most frequent adverse events are gastrointestinal—nausea, diarrhea, vomiting, and constipation—typically emerging during dose escalation and generally mild to moderate in severity. While these symptoms often resolve over time, clinicians should monitor for persistence or intolerance, as discontinuation, though uncommon, can occur. Serious but rare risks include pancreatitis and gallbladder disease; patients presenting with severe abdominal pain warrant immediate evaluation. Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent data, with uncertain relevance to humans. It is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2. Physicians should counsel patients on recognizing symptoms such as neck swelling or persistent hoarseness. Additional precautions include vigilance for severe gastrointestinal symptoms, hypersensitivity reactions, and pancreatitis. Use during pregnancy is not recommended, and effective contraception should be discussed. Finally, consider potential drug interactions and reinforce lifestyle interventions to optimize outcomes alongside pharmacotherapy.*

    20 min
  3. 10/23/2025

    Episode 121: Endocrine Challenges and Advances in Patients with Obesity

    In this sixth episode of our eight part series, Dr. Allison Rhodes welcomes back Dr. Megha Poddar, MD, FRCPC, DABOM, to explore the unique challenges of managing endocrine disorders in patients with obesity. They discuss the complexities of medication dosing and efficacy, diagnostic limitations, and barriers to lifestyle change, along with the long-term management of diabetes, PCOS, and thyroid disease and their impact on metabolic and reproductive health. The conversation also highlights exciting advances in endocrine care, updates in fertility and PCOS management, and the integration of metabolic surgery into treatment plans. Together, Dr. Rhodes and Dr. Poddar emphasize the importance of a compassionate, patient-centered approach that addresses the interconnected nature of hormone and metabolic health to support better long-term outcomes. This podcast offers 0.5 AMA PRA Category 1 Credits™. To claim credit please visit the OMA Academy.  *This activity is supported by an independent educational grant from Novo Nordisk Inc. Episode Guest: Megha Poddar, MD, FRCPC, DABOM is an endocrinologist and obesity medicine specialist, Medical Director of the Medical Weight Management Centre of Canada, and Assistant Clinical Professor at McMaster University Host: Allison Rhodes, MD, FOMA, Obesity Medicine Physician with the Comprehensive Weight Management Program at The Ohio State University Wexner Medical Center

    26 min
4.6
out of 5
58 Ratings

About

Obesity: A Disease is the official Obesity Medicine Association (OMA) FREE podcast exploring the many facets of the disease of obesity. Episodes provide valuable insights into this growing problem and better equip clinicians to understand and engage in treating this disease.

You Might Also Like